Drug Overview 2018: Aristada (Aripiprazole Lauroxil; Alkermes): A Long-Acting Injectable Formulation of the Atypical Antipsychotic Aripiprazole - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Aristada" report has been added to ResearchAndMarkets.com's offering.

Aristada (aripiprazole lauroxil; Alkermes) is a long-acting injectable formulation of the atypical antipsychotic aripiprazole.

It was developed by Alkermes using its proprietary LinkeRx technology, which allows the gradual release of aripiprazole molecules and lowers the drug's frequency of administration.

Aristada acts as partial agonist at dopamine D2 and serotonin 5-hydroxytryptamine (HT)1A receptors, and displays antagonist activity at 5-HT2A receptors. This results in lower dopamine mesolimbic levels, and enhanced dopaminergic activity in the mesocortical pathway. Low levels of mesocortical dopamine appear to cause schizophrenia's negative symptoms, while an excess of mesolimbic dopamine is associated with positive symptoms.

In October 2015, Aristada was approved in the US for the treatment of schizophrenia. The drug is not currently being developed for the Japanese or EU markets.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Aristada: Schizophrenia

List of Figures

Figure 1: Aristada for schizophrenia - SWOT analysis

Figure 2: Drug assessment summary of Aristada for schizophrenia

Figure 3: Drug assessment summary of Aristada for schizophrenia

Figure 4: Aristada sales for schizophrenia in the US, 2017-26

List of Tables

Table 1: Aristada drug profile

Table 2: Aristada pivotal trial data in schizophrenia

Table 3: Aristada other late-phase trial data in schizophrenia

Table 4: Aristada ongoing trial in schizophrenia

Table 5: Aristada sales for schizophrenia in the US ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/ffhl42/drug_overview?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Schizophrenia Drugs